Last update 21 Nov 2024

Dilanubicel

Overview

Basic Info

Drug Type
Hematopoietic stem cell therapy
Synonyms
Ex vivo expanded universal donor cellular therapies Nohla Therapeutics, Ex vivoexpanded cord blood progenitor cells, Haematopoetic progenitor cell therapy Nohla Therapeutics
+ [3]
Target-
Mechanism
Cell replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Acute Biphenotypic Leukemiaacute leukemiaAcute Lymphoblastic Leukemia+ [4]
Inactive Indication
Acute Erythroblastic LeukemiaAcute Megakaryoblastic LeukemiaAcute Radiation Syndrome+ [5]
Originator Organization
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
Active Organization
National Cancer InstituteNational Cancer InstituteFred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research CenterNohla Therapeutics, Inc.Nohla Therapeutics, Inc.
+ [1]
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Related

7
Clinical Trials associated with Dilanubicel
NCT04083170 / TerminatedPhase 2IIT
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
NCT03399773 / RecruitingPhase 2IIT
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
NCT03301597 / TerminatedPhase 2
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia
100 Clinical Results associated with Dilanubicel
Login to view more data
100 Translational Medicine associated with Dilanubicel
Login to view more data
100 Patents (Medical) associated with Dilanubicel
Login to view more data
100 Deals associated with Dilanubicel
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Biphenotypic LeukemiaPhase 2
US
National Cancer InstituteNational Cancer Institute
10 May 2022
Acute Biphenotypic LeukemiaPhase 2
US
Nohla Therapeutics, Inc.Nohla Therapeutics, Inc.
10 May 2022
acute leukemiaPhase 2
US
National Cancer InstituteNational Cancer Institute
10 May 2022
acute leukemiaPhase 2
US
Nohla Therapeutics, Inc.Nohla Therapeutics, Inc.
10 May 2022
acute leukemiaPhase 2
US
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
10 May 2022
Acute Lymphoblastic LeukemiaPhase 2
US
Nohla Therapeutics, Inc.Nohla Therapeutics, Inc.
10 May 2022
Acute Lymphoblastic LeukemiaPhase 2
US
Fred Hutchinson Cancer Research CenterFred Hutchinson Cancer Research Center
10 May 2022
Acute Lymphoblastic LeukemiaPhase 2
US
National Cancer InstituteNational Cancer Institute
10 May 2022
Acute Myeloid LeukemiaPhase 2
US
Deverra Therapeutics, Inc.Deverra Therapeutics, Inc.Startup
-
LeukopeniaPreclinical
US
Nohla Therapeutics, Inc.Nohla Therapeutics, Inc.
21 Jan 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2024
Not Applicable
-
-
ehwyaxzubi(sajiyewzek) = swjvnapvrx xkiepubogc (wprrnscuqk )
View more
-
07 Dec 2024
NCT01690520 (CTgov)
Phase 2
Relapsing acute myeloid leukemia | Acute Lymphoblastic Leukemia | Philadelphia chromosome positive chronic myelogenous leukemia | Acute Biphenotypic Leukemia | Myelodysplastic Syndromes
163
(Arm I (Standard of Care))
(jqzphpldrm) = uddnabupqu bhwznpowtv (xpvvjhrdsl, rentaxnmpm - nmujcbbqcz)
View more
-
06 Jul 2021
(Arm II (Experimental))
(jqzphpldrm) = smxtsfpdik bhwznpowtv (xpvvjhrdsl, ohdonkvlhk - hykzyeogcg)
View more
NCT01690520 (GlobeNewswire)
ManualManual
Phase 2
Hematologic Neoplasms
16
onpdscadfg(ulmkqcbeds) = jnougyrslj glgsxoevsi (avtzdghrwm )
View more
Positive
15 Jun 2018
Standard of Care
onpdscadfg(ulmkqcbeds) = idiovqffzu glgsxoevsi (avtzdghrwm )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free